---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007000"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:28:31.614518+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart

## Summary
- Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).
- Austedo revenue $618M (+38% YoY); 2025 outlook raised to $2.05B-$2.15B (from $1.95B-$2.05B).
- Non-GAAP operating margin 28.9% (+86 bps YoY); on track for 30% target by 2027.
- Exclusive TAPI sale discussions terminated; renewed sales process initiated; divestiture intent maintained.
- Full-year 2025 non-GAAP EPS guidance raised to $2.55-$2.65 (midpoint +$0.025); FCF unchanged $1.6B-$1.9B.

## SEC filing metadata
- accession: 0001171843-25-007000
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/0001171843-25-007000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/f8k_110525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007000
- JSON: https://secwatch.observer/filing/0001171843-25-007000.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.